PMID- 34603052
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211005
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 12
DP  - 2021
TI  - Emerging Applications of Metabolomics to Assess the Efficacy of Traditional 
      Chinese Medicines for Treating Type 2 Diabetes Mellitus.
PG  - 735410
LID - 10.3389/fphar.2021.735410 [doi]
LID - 735410
AB  - Diabetes is a common and complex disease that can exacerbate the complications 
      related to cardiovascular disease, and this is especially true for type 2 
      diabetes mellitus (T2DM). In addition to the standard pharmacological therapies, 
      T2DM has also been treated with nonconventional regimens such as traditional 
      Chinese medicine (TCM), e.g., herbal medicines and TCM prescriptions, although 
      the mechanisms underlying the therapeutic benefits remain unclear. In this 
      regard, many studies have used metabolomics technology to elucidate the basis for 
      the efficacy of TCM for T2DM. Metabolomics has recently attracted much attention 
      with regard to drug discovery and pharmacologically relevant natural products. In 
      this review, we summarize the application of metabolomics to the assessment of 
      TCM efficacy for treating T2DM. Increasing evidence suggests that the metabolic 
      profile of an individual patient may reflect a specific type of T2DM syndrome, 
      which may provide a new perspective for disease diagnosis. In addition, TCM has 
      proved effective for countering the metabolic disorders related to T2DM, and this 
      may constitute the basis for TCM efficacy. Therefore, further determining how TCM 
      contributes to the reversal of metabolic disorders, such as using network 
      pharmacology or by assessing the contribution of host-gut microbiota 
      interactions, will also provide researchers with new potential targets for 
      pharmacologic-based therapies.
CI  - Copyright (c) 2021 Zhang, Yang, Ding, Wang, Xiao and Xiao.
FAU - Zhang, Yumeng
AU  - Zhang Y
AD  - The Ministry of Education (MOE) Key Laboratory for Standardization of Chinese 
      Medicines, Institute of Chinese Materia Medica, Shanghai University of 
      Traditional Chinese Medicine, Shanghai, China.
FAU - Yang, Yingbo
AU  - Yang Y
AD  - The Ministry of Education (MOE) Key Laboratory for Standardization of Chinese 
      Medicines, Institute of Chinese Materia Medica, Shanghai University of 
      Traditional Chinese Medicine, Shanghai, China.
AD  - Jiangsu Kanion Pharmaceutical Co., Ltd., Lianyungang, China.
FAU - Ding, Lili
AU  - Ding L
AD  - The Ministry of Education (MOE) Key Laboratory for Standardization of Chinese 
      Medicines, Institute of Chinese Materia Medica, Shanghai University of 
      Traditional Chinese Medicine, Shanghai, China.
FAU - Wang, Zhengtao
AU  - Wang Z
AD  - The Ministry of Education (MOE) Key Laboratory for Standardization of Chinese 
      Medicines, Institute of Chinese Materia Medica, Shanghai University of 
      Traditional Chinese Medicine, Shanghai, China.
FAU - Xiao, Ying
AU  - Xiao Y
AD  - The Ministry of Education (MOE) Key Laboratory for Standardization of Chinese 
      Medicines, Institute of Chinese Materia Medica, Shanghai University of 
      Traditional Chinese Medicine, Shanghai, China.
FAU - Xiao, Wei
AU  - Xiao W
AD  - The Ministry of Education (MOE) Key Laboratory for Standardization of Chinese 
      Medicines, Institute of Chinese Materia Medica, Shanghai University of 
      Traditional Chinese Medicine, Shanghai, China.
AD  - Jiangsu Kanion Pharmaceutical Co., Ltd., Lianyungang, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210917
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC8486080
OTO - NOTNLM
OT  - metabolic regulation
OT  - metabolome
OT  - metabolomics
OT  - traditional Chinese medicine
OT  - type 2 diabetes
COIS- Authors YY and WX were employed by the company Jiangsu Kanion Pharmaceutical Co., 
      Ltd. The remaining authors declare that the research was conducted in the absence 
      of any commercial or financial relationships that could be construed as a 
      potential conflict of interest.
EDAT- 2021/10/05 06:00
MHDA- 2021/10/05 06:01
PMCR- 2021/09/17
CRDT- 2021/10/04 05:56
PHST- 2021/07/02 00:00 [received]
PHST- 2021/09/08 00:00 [accepted]
PHST- 2021/10/04 05:56 [entrez]
PHST- 2021/10/05 06:00 [pubmed]
PHST- 2021/10/05 06:01 [medline]
PHST- 2021/09/17 00:00 [pmc-release]
AID - 735410 [pii]
AID - 10.3389/fphar.2021.735410 [doi]
PST - epublish
SO  - Front Pharmacol. 2021 Sep 17;12:735410. doi: 10.3389/fphar.2021.735410. 
      eCollection 2021.